A Randomized Controlled Trial of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nausea and Vomiting

Inclusion Criteria

• •Male or female aged ≥ 18years
• •Histologically and/or cytologically confirmed cancer
• •The physical status score ECOG ≤ 2
• •Life expectancy of ≥3 months
• •Will receive multi-day ME/HE chemotherapy (≥2 days) with the emetogenic potential of level 3-5
• •In accordance with the indication of chemotherapy and basic requirements;
• •* Peripheral Haematology: Hb ≥ 9.0 g/dL, absolute neutrophil count ≥ 1.5×10e9/L, platelet count ≥ 80×10e9/L
• •* Blood biochemistry: Total bilirubin \< 1.25×ULN, ALT and AST ≤ 2.5×ULN; if liver metastasis, ALT and AST \< 5×ULN, Creatinine ≤ 1×ULN, basic normal serum electrolyte (Na, Ka, Cl, Ca)
• •* Other important organs function normally
• •Subjects voluntarily participate and signed the informed consent form